ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,00%
Bitcoin
66.931,23
-0,22%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Indaptus Therapeutics Inc (INDP)

  7. Indaptus Therapeutics Inc (INDP) News

INDP

Indaptus Therapeutics (INDP)

Indaptus Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:INDP
DatumZeitQuelleÜberschriftSymbolFirma
08/05/202414h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INDPIndaptus Therapeutics Inc
08/05/202414h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
08/05/202414h00GlobeNewswire Inc.Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
11/04/202413h30GlobeNewswire Inc.Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
28/03/202413h00GlobeNewswire Inc.Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
25/03/202413h30GlobeNewswire Inc.Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
18/03/202413h00GlobeNewswire Inc.Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024NASDAQ:INDPIndaptus Therapeutics Inc
13/03/202412h30GlobeNewswire Inc.Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
04/03/202417h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
04/03/202413h30GlobeNewswire Inc.Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortNASDAQ:INDPIndaptus Therapeutics Inc
15/02/202414h00GlobeNewswire Inc.Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
08/02/202414h00GlobeNewswire Inc.Indaptus Therapeutics Expands Digital Presence with Launch of Social Media ChannelsNASDAQ:INDPIndaptus Therapeutics Inc
23/01/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INDPIndaptus Therapeutics Inc
23/01/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
04/01/202414h00GlobeNewswire Inc.European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform TechnologyNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202322h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INDPIndaptus Therapeutics Inc
06/11/202322h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202322h01GlobeNewswire Inc.Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202314h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202314h00GlobeNewswire Inc.Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 StudyNASDAQ:INDPIndaptus Therapeutics Inc
31/10/202314h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
31/10/202314h01GlobeNewswire Inc.Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy MeetingNASDAQ:INDPIndaptus Therapeutics Inc
27/09/202314h00GlobeNewswire Inc.Indaptus Therapeutics to Present at the LD Micro Main Event XVINASDAQ:INDPIndaptus Therapeutics Inc
26/09/202314h00GlobeNewswire Inc.Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023NASDAQ:INDPIndaptus Therapeutics Inc
19/09/202314h00GlobeNewswire Inc.Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20NASDAQ:INDPIndaptus Therapeutics Inc
06/09/202314h05GlobeNewswire Inc.Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
17/08/202300h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INDPIndaptus Therapeutics Inc
14/08/202314h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INDPIndaptus Therapeutics Inc
14/08/202314h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
14/08/202314h00GlobeNewswire Inc.Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:INDP

Kürzlich von Ihnen besucht

UNSW3
LYNKUSDT
LynKey
AMEX
QWST
Harbor Small Cap Explore...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten